论文部分内容阅读
目的:探讨紧密连接蛋白1(claudin-1,Cldn-1)和上皮钙黏蛋白(E-cadherin,E-cad)在乳腺癌组织中的表达及其与乳腺癌侵袭转移的关系。方法:应用组织芯片技术和免疫组化法检测77例乳腺癌标本中Cldn-1和E-cad的表达情况,并分析两者与乳腺癌淋巴结转移、TNM分期和肿块最大径以及组织学分级间的关系。结果:Cldn-1和E-cad表达强度与乳腺癌的淋巴结转移及临床分期有关,有淋巴结转移的乳腺癌组Cldn-1和E-cad表达强度明显弱于无淋巴结转移组(P=0.0009,P=0.014);Cldn-1在TNMIII期的表达强度分别弱于I期和II期(P=0.046,P=0.047)。而E-cad的表达强度II期及III期均弱于I期(P=0.021,P=0.001)。Cldn-1和E-cad表达强度与肿块最大径各分组间及组织学各分级之间差异无统计学意义(P=0.967,P=0.150及P=0.188,P=0.164)。Cldn-1与E-cad两者在乳腺癌组织中的表达强度差异无统计学意义(P=0.747)。结论:在乳腺癌的发展和转移中Cldn-1及E-cad的表达强度均呈现减弱趋势,但两者可能是独立的因素;联合检测有助于对乳腺癌高复发危险性的筛选,两者可作为判断乳腺癌淋巴结转移、复发和评估预后的参考指标。
Objective: To investigate the expression of claudin-1 (Cldn-1) and E-cadherin (E-cad) in breast cancer and its relationship with invasion and metastasis of breast cancer. Methods: The expression of Cldn-1 and E-cad in 77 breast cancer specimens were detected by tissue microarray and immunohistochemistry. The relationship between the expression of Cldn-1 and E-cad in breast cancer was analyzed. Relationship. Results: The expression of Cldn-1 and E-cad was correlated with lymph node metastasis and clinical stage in breast cancer. The expression of Cldn-1 and E-cad in breast cancer with lymph node metastasis was significantly lower than that without lymph node metastasis (P = 0.0009, P = 0.014). The expression of Cldn-1 in TNMI II stage was weaker than that in stage I and II (P = 0.046, P = 0.047). The expression of E-cad in stage II and III were weaker than in stage I (P = 0.021, P = 0.001). There was no significant difference between the expression of Cldn-1 and E-cad expression and the maximum diameter of the tumor (P = 0.967, P = 0.150 and P = 0.188, P = 0.164). There was no significant difference in the expression intensity of Cldn-1 and E-cad in breast cancer (P = 0.747). CONCLUSION: The expression of Cldn-1 and E-cad in breast cancer are weakened in the development and metastasis, but both may be independent factors. Combined detection may be helpful to screen the high risk of recurrent breast cancer. Can be used as a reference to determine the prognosis of breast cancer lymph node metastasis, recurrence and assessment.